ArticleThe European respiratory journal2020
Quantitative analysis of airway obstruction in lymphangioleiomyomatosis.
Article in The European respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Uncovering underdiagnosed emphysema: comparative assessment using clinical CT and micro-CT.European radiology · 2026Article
- Evolution of cystic lung disease in Birt-Hogg-Dubé syndrome: assessment of older patients.BMJ open respiratory research · 2025Article
- Age-related lung structure changes by quantitative assessment: a cross-sectional study in a Chinese male cohort.Frontiers in aging · 2025Article
- The role of moesin in diagnosing and assessing severity of lymphangioleiomyomatosis.Respiratory research · 2024Article
- Small airways morphological alterations associated with functional impairment in lymphangioleiomyomatosis.BMC pulmonary medicine · 2024Article
- Unexpected sirolimus-stimulated airway hyperreactivity in lymphangioleiomyomatosis.ERJ open research · 2023Article
- Radiologic and Histologic Correlates of Early Interstitial Lung Changes in Explanted Lungs.Radiology · 2023Article
- Angiotensin-Converting Enzyme 2 (ACE2), Transmembrane Peptidase Serine 2 (TMPRSS2), and Furin Expression Increases in the Lungs of Patients with Idiopathic Pulmonary Fibrosis (IPF) and Lymphangioleiomyomatosis (LAM): Implications for SARS-CoV-2 (COVID-19) Infections.Journal of clinical medicine · 2022Article
- From Macroscopy to Ultrastructure: An Integrative Approach to Pulmonary Pathology.Frontiers in medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphangioleiomyomatosis (LAM) is a rare, cystic lung disease with progressive pulmonary function loss caused by progressively proliferating LAM cells. The degree of airway obstruction has not been well investigated within the pathogenesis of LAM.Using a combination of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.